Announcement • May 22
Skye Bioscience Announces Cohort Review Committee Approves Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1 Skye Bioscience, Inc. announced that the Cohort Review Committee (CRC) responsible for reviewing safety data generated from the CBeyond Part C Expansion Study, and for approving the opening of enrollment in Cohort 2 has unanimously approved opening the second cohort of the CBeyond Part C Expansion study. The CRC focuses exclusively on the safety of the Part C Expansion Study and does not conduct efficacy assessments. The independent Data Monitoring Committee (DMC) continues to have safety oversight for the study. The Expansion Study comprises two cohorts of nimacimab monotherapy (400 mg IV and 600 mg IV) compared with placebo, administered weekly over 15 weeks (16 doses), with a 12-week follow-up period, to generate preliminary safety and PK data with higher doses. Within each dose cohort, 8 participants will be randomized in a 3:1 ratio to nimacimab (n=6) or placebo (n=2). The CRC approved enrollment in Cohort 2 (600 mg IV) based on a favorable safety review of the first participants who completed 4 weeks of treatment in Cohort 1 (400 mg IV). No serious adverse events or adverse events of special interest were reported following 4 weeks of treatment. Board Change • May 20
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 1 experienced director. 1 highly experienced director. President, CEO & Director Punit Dhillon is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • May 16
Skye Bioscience, Inc. Announces Notice of Non-Compliance with Nasdaq Global Market Listing Rule On May 13, 2026, Skye Bioscience, Inc. (the Company" or Skye") received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq") notifying the Company that, based on the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, the Company's stockholders' equity was $9,011,804, and therefore, the Company was not in compliance with Nasdaq Global Market's Listing Rule 5450(b)(1)(A), which requires a $10,000,000 minimum stockholders' equity standard. The Notice has no immediate effect on the listing or trading of the Company's common stock, par value $0.001 per share (the common stock") on the Nasdaq Global Market and the common stock will continue to trade under the symbol SKYE". Pursuant to Nasdaq Marketplace Rule 5810(c)(2)(C), the Company has been provided 45 calendar days, or until June 29, 2026, to supply a specific plan to regain compliance with all Nasdaq Global Market listing requirements and the Company's time frame to complete its plan. If the plan is accepted, Nasdaq can grant an extension of up to 180 calendar days from the date of the Notice, or until November 9, 2026, to evidence compliance. If the plan is not accepted, the Company will have the right to appeal and the common stock would remain listed on The Nasdaq Global Market until the completion of the appeal process. To regain compliance, the Company must have stockholders' equity of at least $10,000,000. The Company is currently evaluating various alternative courses of action to regain compliance. There can be no assurance that the Company will be able to regain compliance with the minimum stockholders' equity requirement or maintain compliance with the other listing requirements. 
